Teva Announces U.S. FDA Approval of Three-Times-a-Week COPAXONE(R) (glatiramer acetate injection) 40mg/mL
New Formulation of COPAXONE® Offers Patients and Their Physicians Ability to Dose Less Frequently
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd. (TEVA) announced today that the U.S. Food and Drug Administrat... Biopharmaceuticals, Neurology, FDATeva Pharmaceutical, COPAXONE, Glatiramer, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 29, 2014 Category: Pharmaceuticals Source Type: news
Teva secures FDA approval for new formulation of COPAXONE
Israel-based Teva Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for its supplemental new drug application (sNDA) for three-times-a-week COPAXONE 40mg/mL, a new dose of COPAXONE (glatiramer acetate injection) ind… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 29, 2014 Category: Pharmaceuticals Source Type: news
Less frequent Copaxone
The FDA, the American drug regulator, has approved a new dose of glatiramer acetate (Copaxone) that is injected three times a week rather than daily (both versions will be available) .
Teva press release
Glatiramer acetate (Copaxone) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - January 28, 2014 Category: Neurology Source Type: news
Teva's Last Ditch Effort to Save Copaxone Patent
Teva Pharmaceutical Industries has petitioned the US Supreme Court to review a lower court ruling from July 2013 that had cut more than a year off the legal protection for Copaxone. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 22, 2014 Category: Pharmaceuticals Source Type: news
Flu vaccine and disease modifying drugs
Norwegian research found that people with MS taking glatiramer acetate (Copaxone), natalizumab (Tysabri) or mitoxantrone had a less effective response to the H1N1 and seasonal flu vaccinations. People taking beta interferon showed no reduction.
MSIF
Flu immunisation - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - January 21, 2014 Category: Neurology Source Type: news
Gene Expression Analysis Shows Varying Reactions to Teva's COPAXONE (GA) vs a Generic
Teva Pharmaceuticals announced the release of data demonstrating substantial differences in biological and immunological effects concerning its product Copaxone (glatiramer acetate, GA) and a generic GA commercialized in India. Copaxone is indicated for decreasing relapse frequency in relapsing remitting multiple sclerosis (MS). Multiple sclerosis affects more than 2 million people all over the world. The published data holds possibilities for clinical ramifications. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - January 16, 2014 Category: Pharmaceuticals Source Type: news
Supreme Court Rejects Teva's Bid to Protect Copaxone Patent
A U.S. Supreme Court justice refused to stay a ruling that would open Teva Pharmaceutical Industries' Copaxone multiple-sclerosis drug to generic competition in May 2014. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 20, 2013 Category: Pharmaceuticals Source Type: news
Teva asks U.S. justices for stay in Copaxone case
WASHINGTON (Reuters) - Teva Pharmaceutical Industries on Monday asked the U.S. Supreme Court to stay an appeals court ruling that would strip its $4 billion-a-year multiple sclerosis drug Copaxone of its patent protection in 2014 rather than 2015. (Source: Reuters: Health)
Source: Reuters: Health - November 4, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Teva Pharm faces U.S. patent worries, dip in profits
JERUSALEM (Reuters) - Teva Pharmaceutical Industries profits fell in the second quarter, hurt by a decline in U.S. and European generic drug sales, and its near-term outlook looks bleak in the face of prospective competition for multiple sclerosis drug Copaxone. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Natco Pharma gets favourable ruling for Copaxone in US
Natco Pharma on Saturday said it has obtained a favourable ruling from a US Court that paves way for launch of generic Copaxone. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 27, 2013 Category: Pharmaceuticals Source Type: news
U.S. court permits generic version of Teva MS drug a year sooner
WASHINGTON/NEW YORK (Reuters) - Teva Pharmaceutical Industries' $4 billion-a-year multiple sclerosis drug Copaxone will lose its patent protection in 2014 rather than 2015 because of a ruling from a U.S. appeals court on Friday, making it potentially prey to cheaper generics next May. (Source: Reuters: Health)
Source: Reuters: Health - July 26, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
Less frequent Copaxone study
Publication of the previously presented GALA study research that shows that a larger dose of glatiramer acetate taken three times a week is as effective as the current daily injection.
Teva press release in the Wall Street Journal
Disease modifying drugs for relapsing MS - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 30, 2013 Category: Neurology Source Type: news
Less frequent Copaxone
A version of glatiramer acatate (Copaxone) that requires injections three times a week instead of every day has been submitted for a review by the FDA, the drug regulatory body in the USA, in advance of application for a licence.
PharmaBiz
Glatiramer acatate (Copaxone) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - May 31, 2013 Category: Neurology Source Type: news
AAN meeting review
An interview with Dr Lawrence Steinman, Professor of Neurology at Stanford University in California, looks at topics raised at the recent AAN (American Academy of Neurology) meeting. Topics covered include repurposing already approved drugs, the Avonex/Copaxone combination therapy and approaches to secondary progressive MS.
Medscape (requires free registration)
Latest MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - April 2, 2013 Category: Neurology Source Type: news
Drug research from the AAN meeting
Another round up of information presented at the recent AAN (American Academy of Neurology) meeting about disease modifying drugs - includes fingolimod, teriflunomide, pegylated interferon, glatiramer acetate and a combination treatment.
MedPage Today
MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - March 27, 2013 Category: Neurology Source Type: news
